Jeff Weisel, Senior Advisor, Asia Pacific at PRMA Consulting, explores why the shifting currents of global healthcare are dictating a new approach to market access.The healthcare landscape is changing and the basic principles of pricing, reimbursement, and time to market are no longer sufficient to meet the needs of the industry.
During the last 10 years we have experienced the emergence of targeted therapies serving smaller patient populations. The launch timeline has also become faster, and the rapid development of COVID-19 vaccines demonstrates how the drug development process could become more streamlined in the future. This article explores how the landscape is shifting and why we need to redefine the market access model to meet the challenges the industry will face in the next decade.
Read the insight here.